Global Human Papillomavirus Infection Drug Markets & Clinical Trial Insight 2017-2023: 9 HPV Drugs Commercially Available in the Market and 78 Drugs are in Multiple Phases of Clinical Pipeline

Dublin, Sept. 19, 2017 -- The "Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023" report has been added to Research and Markets' offering.

Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023 report gives comprehensive insight on the ongoing market and clinical development in HPV drug market.

Report highlights the trends in the global HPV drug market and gives detailed overview on the HPV drug clinical pipeline by phase, drug class and mode of action. As per report findings, there are 9 HPV drugs commercially available in the market and 78 drugs are in multiple phases of clinical pipeline. Majority of the HPV drugs are in Preclinical phase of development followed by Phase-II clinical trials.

In the past decade, there have been remarkable advances in the understanding of the natural history of human papillomavirus (HPV) infection and its role as the major risk factor in the development of cervical and other anogenital cancers, which has led to increased research and development in the HPV drug segment; thus leading to the introduction of excellent and promising therapeutics in the Human Papilloma virus drug segment.

Among the various therapeutics currently available for Human Papilloma virus infection, is the Human Papilloma Virus Vaccine which is currently the dominant form of medication in the HPV therapeutic segment. These Vaccines are considered to be the most superior kinds of therapeutics due to their ability to provide long term protection from Human Papilloma Virus. Apart from being safe and effective, these have been in wide use in the vaccination of preteen girls and boys in US and other developed countries to ensure their long term protection and prevention from exposure to the Human Papilloma virus.

Further, these vaccines also ensure high efficacy in preventing genital warts, anal cancer, cervical cancer, vulvar cancer and vaginal cancer which are widely known to be caused by certain types of human papilloma virus. It has also been used in the prevention of lesions that are caused by the Human Papilloma virus which can lead to the above mentioned complications.

Global Human Papillomavirus Infection Drug Market & Clinical Trials Insight 2023 Report Highlights:

• Global Human Papillomavirus Infection Market Analysis
• Global Human Papillomavirus Infection Drug Market Dynamics
• Clinical Insight on Approved Drugs for Treating Human Papillomavirus Infection
• Global Human papillomavirus Infections Drug Clinical Pipeline by Company & Phase
• Global Human Papillomavirus Infection Drug Market Future Perspective
  

Key Topics Covered:

1. Introduction to Human Papillomavirus Infection

• Pathogenicity & Diversity of Human Papillomavirus

2. Pathophysiology of Human Papillomavirus

• Life Cycle of Human Papillomavirus
• Molecular Mechanism of Human Papillomavirus to Induce Disease

3. Response of Immune System Against Human Papillomavirus

• Innate Immunity
• Adaptive Immunity

4. Clinical Management Strategies Against Human Papillomavirus Infection

• Vaccination Approach for Human Papillomavirus
• Therapeutic Drugs Targets

5. Emerging Therapies for Treatment of Infection

• Live Vector based Vaccines
• Protein or Peptide based Vaccines
• Nucleic Acid based Vaccines
• Whole Cell based Vaccines

6. Approved Drugs for Treating Human Papillomavirus Infection: Clinical, Drug Class & Patent Insight

• Human Papillomavirus Vaccine Recombinant Quadrivalent (Gardasil & Silgard)
• Interferon alpha-2b (Intron A, Viraferon & Virtron)
• Tretinoin (Acnisdin Retinoico, Avita, Dermojuventus, Loderm Retinoico, Retirides, Vesanoid, Vitamin-A Acid & Vitanol)
• Imiquimod (Aldara, Beselna Cream 5%, Vyloma & Zyclara)
• Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix)
• Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
• Interferon-alpha-n3 (Alferon LDO, Alferon N, Alferon N Gel, Alferon N Injection, Alferon N LDO, Altemol & Naturaferon)
• Polyphenon E (Polyphenon E & Veregen)
• Interferon Gamma Biosimilar (Ingaron)

7. Global Human Papillomavirus Infection Market Analysis

• Introduction to Infectious Disease Market
• Global Human Papillomavirus Market Analysis

8. Global Human Papillomavirus Infection Drug Market Dynamics

• Favorable Parameters
• Challenges to Market Growth

9. Global Human Papillomavirus Infection Drug Market Future Perspective

10. Global Human papillomavirus Infections Drug Clinical Pipeline by Company & Phase

• Research
• Preclinical
• Phase-I
• Phase-I/II
• Phase-II
• Phase-II/III
• Phase-III

11. Competitive Landscape

• 3M Pharmaceuticals
• Aclaris Therapeutics
• Biogen Idec
• Cutanea Life Sciences
• Hemispherx
• Inovio Pharmaceuticals
• ISA Pharmaceuticals
• Lees Pharmaceutical Holdings
• MedImmune
• Merck
• Mylan Pharmaceuticals
• Nielsen BioSciences
• Novan

For more information about this report visit https://www.researchandmarkets.com/research/ln5tdt/global_human

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Infectious Diseases Drugs, Infectious Diseases Drugs, Clinical Trials, Sexual and Reproductive Health Drugs